Clinical Trial

Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy

Study acronym: PRONECAP
Recruiting
View on ClinicalTrials.gov →
Summary
Community acquired pneumonia, in particular when requiring oxygen therapy because of acute hypoxemic respiratory failure and meeting acute respiratory distress syndrome (ARDS) criteria frequently leads to tracheal intubation and poor outcome. Among invasively mechanically ventilated patients with ARDS and presenting a PaO2/FiO2 ratio (arterial partial pressure of oxygen to inspired fraction of oxygen) of less than 150 mmHg, the prone position significantly reduces mortality and represents standard care (Guérin 2013). Among non-intubated COVID-19 patients, a subtype of viral community acquired pneumonia, a recent study showed that awake prone positioning reduces the composite outcome of intubation or death among patients requiring nasal high flow therapy. Furthermore, it favored weaning of nasal high flow therapy. Prone position in patients with non-COVID ARDS treated with high nasal flow was evaluated in 20 patients with predominantly viral pneumonia (Ding 2020) and was associated with improved oxygenation. Coordinating investigator hypothesize that prone positioning of patients suffering non-COVID community acquired pneumonia and undergoing nasal high flow therapy can significantly improve outcome by reducing the need for intubation and associated therapies such as sedation and muscle relaxation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-02.
Status change: Not Yet Recruiting → Recruiting 2026-04-28
Trial Details
NCT Number NCT06966310
Lead Sponsor University Hospital, Tours
Conditions Community-acquired Pneumonia
Enrollment 1,078 participants
Start Date 2025-11-30
Primary Completion 2029-11 (estimated)
Study Completion 2034-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-04